Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
21 studies found for:    CNTO1959
Show Display Options
Rank Status Study
1 Active, not recruiting An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
Condition: Pustular Psoriasis
Intervention: Drug: Guselkumab
2 Completed A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis
Condition: Psoriasis
Intervention: Drug: CNTO 1959; Placebo
3 Completed A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis
Condition: Palmoplantaris Pustulosis
Interventions: Drug: Placebo;   Drug: CNTO 1959
4 Completed A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: CNTO 1959;   Drug: Placebo
5 Recruiting An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
Condition: Psoriasis
Interventions: Drug: CNTO 1959 50 mg;   Drug: CTNO 1959 100 mg;   Drug: Placebo 50 mg;   Drug: Placebo 100 mg
6 Completed A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants
Condition: Healthy
Interventions: Drug: Guselkumab (lyophilized formulation);   Drug: Guselkumab (liquid formulation with PFS-U);   Drug: Guselkumab (liquid formulation with PFS FID);   Drug: Guselkumab (liquid formulation)
7 Completed A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis
Condition: Psoriasis
Interventions: Drug: CNTO 1959 (5 mg);   Drug: CNTO 1959 (15 mg);   Drug: CNTO 1959 (50 mg);   Drug: CNTO 1959 (100 mg);   Drug: CNTO 1959 (200 mg);   Drug: Adalimumab;   Drug: Placebo
8 Completed
Has Results
A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy
Condition: Arthritis, Rheumatoid
Interventions: Drug: Placebo + methotrexate (MTX) (Group 1);   Drug: Ustekinumab + MTX (Group 2);   Drug: Ustekinumab + MTX (Group 3);   Drug: CNTO 1959 + MTX (Group 4);   Drug: CNTO 1959 + MTX (Group 5)
9 Completed Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
Condition: Psoriasis
Interventions: Drug: Guselkumab;   Drug: Midazolam;   Drug: Warfarin;   Drug: Omeprazole;   Drug: Dextromethorphan;   Drug: Caffeine
10 Active, not recruiting Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Condition: Psoriasis
Interventions: Drug: Guselkumab;   Drug: Placebo
11 Recruiting A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Condition: Psoriasis
Interventions: Drug: Guselkumab;   Drug: Placebo;   Drug: Secukinumab
12 Active, not recruiting A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
Condition: Psoriasis
Interventions: Drug: Guselkumab 100 mg;   Drug: Placebo for guselkumab;   Drug: Adalimumab;   Drug: Placebo for adalimumab
13 Active, not recruiting A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
Condition: Psoriasis
Interventions: Drug: Guselkumab 100 mg;   Drug: Placebo for guselkumab;   Drug: Adalimumab;   Drug: Placebo for adalimumab
14 Recruiting An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis
Condition: Palmoplantar Pustulosis
Interventions: Drug: Guselkumab;   Drug: Placebo
15 Not yet recruiting A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
Condition: Arthritis, Psoriatic
Interventions: Drug: Guselkumab;   Drug: Placebo
16 Not yet recruiting A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)
Condition: Arthritis, Psoriatic
Interventions: Drug: Guselkumab;   Drug: Placebo
17 Completed A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants
Condition: Healthy
Intervention: Drug: Guselkumab
18 Completed A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Condition: Psoriasis
Interventions: Drug: Ustekinumab;   Drug: Guselkumab;   Drug: Placebo for ustekinumab;   Drug: Placebo for guselkumab
19 Active, not recruiting A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Condition: Psoriasis
Interventions: Drug: Guselkumab;   Drug: Fumaric Acid Esters
20 Completed Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Condition: Psoriatic Arthritis
Interventions: Drug: Guselkumab;   Drug: Ustekinumab;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.